AKT1 and breast carcinoma: These findings establish DUXAP8 as a critical epigenetic regulator of radioresistance in breast cancer via activation of the PI3K/AKT/mTOR pathway and repression of tumor suppressors, highlighting its potential as a therapeutic target.